Journal of Clinical Oncology
Articles in this Issue
Vitamin D serum level as a predictor of response to immunotherapy for non-small cell lung cancer.
e14563 Background: Vitamin D plays a pivotal role in immune system regulation. Immunotherapy is a key treatment modality for patients with advanced-stage...
Pivotal studies of pharmacotherapies approved by the United States Food and Drug Administration for the treatment of cancer: A systematic review.
e23125 Background: The development of pharmacotherapies for cancer treatment has increased significantly. However, an assessment of approvals by the US Fo...
Implementing standardized documentation for goals of care among advanced stage cancer patients.
e23236 Background: Early goals of care (GOC) discussions are associated with better health outcomes and quality of life for patients with advanced cancer....
Real-world survival data analysis in EGFR-mutated NSCLC patients.
e20697 Background: EGFR tyrosine kinase inhibitors (TKIs) have become the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) pa...
Preliminary efficacy of VOICE, a decision support tool for older adults with advanced cancer: A pilot randomized trial.
11094 Background: Quality shared decision-making (SDM) requires integrating patient values into treatment decisions. Many older patients (pts) with cancer...
HERTHENA-Breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancer.
TPS629 Background: The standard of care for patients with high-risk, early-stage TNBC is neoadjuvant pembrolizumab (pembro) + chemotherapy followed by adj...
Phase 1 study of B440, an oral <i>Bifidobacterium</i> -engineered WT1 cancer vaccine, in patients with metastatic urothelial cancer.
2505 Background: B440 is an innovative oral cancer vaccine comprised of recombinant Bifidobacterium engineered to express WT1 tumo...
Common criticisms of the accelerated approvals program: A context and data-driven assessment of overall survival in oncology indications.
e23035 Background: The accelerated approvals (AA) program uses surrogate endpoints to enable early access to promising therapies. The AA program receives...
Advancing treatment outcomes for peritoneal surface malignancies in low- and middle-income countries: Insights from the first multicenter study in north Africa.
e16476 Background: Peritoneal surface malignancies (PSM) are highly aggressive cancers with limited treatment access in low- and middle-income countries (...
STAR-01: A randomized phase III clinical trial comparing PD-1 combined with apatinib and SOX，PD-1 combined with SOX, versus SOX alone in patients with advanced gastric adenocarcinoma.
e16070 Background: Gastric adenocarcinoma is one of the most common malignant tumors. With the recent research, it has been found that positive conversion...
A first-in-class KIF11 degrader antibody conjugate (DAC) as a potential therapy targeting a broad spectrum of cancers.
3092 Background: Kinesin family member 11 (KIF11) plays a critical role in mitotic spindle formation and centrosome separation during cell division, makin...
Examining the effectiveness of laws requiring human papillomavirus vaccination on cervical cancer rates.
e17533 Background: Cervical cancer is a significant global health challenge and ranks as the fourth most common cancer in women worldwide. Human Papilloma...
Immunotherapy in gastrointestinal cancers with pre-existing autoimmune disorders.
e14662 Background: The use of immunotherapy (IT) in patients with gastrointestinal cancers (GIC) with pre-existing autoimmune disorders (AID) presents a c...
Trop2-targeted PET/CT with <sup>68</sup> Ga-MY6349 for detecting metastatic lesions in metastatic thyroid cancer: Prospective comparison of diagnostic accuracy with <sup>18</sup> F-FDG PET/CT.
6104 Background: Trophoblast cell surface antigen 2 (Trop2) targeted molecular imaging with 68 Ga-MY6349 has been proposed as a po...
Development and validation of a postoperative nomogram for predicting survival in gallbladder cancer patients: Insights from SEER and external cohorts.
e16314 Background: Gallbladder cancer (GBC) is a rare but highly lethal malignancy with limited treatment options. Prognostic tools for predicting long-te...
Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).
TPS5118 Background: The median overall survival of patients with mCRPC remains under 2 years even with newer therapies. Xaluritamig, an XmAb 2+1 T-cell en...
The longer, the better: How tokenized linkage can extend observable time for cancer patients in health insurance claims databases.
e23349 Background: Claims databases have become a key to longitudinality in real-world evidence generation for US-based oncology research by extending pat...
IMMUNORARE <sup>5</sup> : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The B3 Thymomas and Thymic Carcinomas Cohort.
TPS8130 Background: In patients with rare cancers, there is an unmet medical need for investigating innovative therapeutics. Indeed, these diseases are ra...
Omitting axillary dissection in patients with 1-2 sentinel node–positive breast cancer undergoing mastectomy in China: A retrospective cohort study with target trial emulation.
e12577 Background: Trials have demonstrated the safety of omitting axillary dissection in patients with cT1-3, cN0, or iN0 breast cancer, and 1-2 sentinel...
Prognostic utility of ctDNA before and after trimodality therapy (TMT) for muscle invasive bladder cancer.
4578 Background: Outside of standard patient and tumor characteristics, biomarkers predicting outcomes after TMT for non-metastatic muscle-invasive bladde...
Early metaplastic breast carcinoma: A rare tumor with unique clinicopathological features and limited response to neoadjuvant therapy—A single institution experience.
e13183 Background: Metaplastic breast carcinoma (MpBC) is a subtype of breast cancer characterized by both epithelial and mesenchymal features. While MpBC...
Prognostic implications of glycemia in non-diabetic patients with metastatic melanoma undergoing immunotherapy.
9530 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the cancer therapeutic landscape, significantly improving the survival of patient...
ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with <i>ESR1</i> -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.
TPS1129 Background: ET+CDK4/6i is standard-of-care (SOC) in 1L ER+/HER2- aBC; however, tumors eventually develop resistance. Constitutive activation in th...
Triplet versus doublet therapy in older patients with metastatic hormone-sensitive prostate cancer: A network meta-analysis.
5088 Background: Multiple treatment options are now available for metastatic hormone-sensitive prostate cancer (mHSPC) with the expanded approval of andro...
Impact of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) on mortality and kidney function in cancer patients receiving cisplatin.
11047 Background: Cisplatin is a cornerstone of cancer treatment, but its nephrotoxicity often requires dose reduction or withdrawal, compromising antitum...